CYP1B1-IN-12 is a selective inhibitor of cytochrome P4501B1 (CYP1B1) with an IC50 value of 6.05 nM. It demonstrates exceptional selectivity, being over 1,600 times more selective for CYP1B1 compared to CYP1A1 and over 16,000 times compared to CYP1A2. CYP1B1-IN-12 enhances Paclitaxel-mediated apoptosis and restores sensitivity of A549/Tax cells to Paclitaxel. It also inhibits epithelial-mesenchymal transition, reducing cell migration and invasion. CYP1B1-IN-12 is applicable in cancer research, such as non-small cell lung cancer (NSCLC).

CYP1B1:6.05 nM

CYP1B1-IN-12 (Compound B14) at 10 μM exhibits less than 50% inhibition of seven major CYP enzymes, including CYP2B6 and CYP2C8, indicating a low potential for drug interactions. An IC50 value greater than 20 μM was observed for Compound B14 (0-20 μM, 48 h) in HUVEC and BEAS-2B cells. In combination with Paclitaxel, CYP1B1-IN-12 (2-8 μM, 48 h) inhibits proliferation of A549/Tax cells in a dose-dependent manner. Additionally, CYP1B1-IN-12 (2-8 μM, 14 days) reduces colony numbers of A549/Tax cells when used with Paclitaxel. The combined treatment of CYP1B1-IN-12 (8 μM, 48 h) and Paclitaxel increases the total apoptotic cell ratio in A549/Tax cells. Furthermore, CYP1B1-IN-12 (1-4 μM, 24 h) restricts migration and invasion of A549/Tax cells. It also upregulates E-cadherin and downregulates N-cadherin and vimentin levels in A549/Tax cells when administered at 1-4 μM for 48 hours.